NASDAQ:HCM - Hutchison China MediTech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 36.94 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$29.21
▲ +0.21 (0.72%)
1 month | 3 months | 12 months
Get New Hutchison China MediTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$40.00
▲ +36.94% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Hutchison China MediTech in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 36.94% upside from the last price of $29.21.
Buy
The current consensus among 2 investment analysts is to buy stock in Hutchison China MediTech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2021MizuhoInitiated CoverageBuyLow
i
10/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$40.00Medium
i
3/12/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
i
Rating by L. Chen at Cantor Fitzgerald
2/20/2020The Goldman Sachs GroupInitiated CoverageBuyLow
i
11/19/2019CLSAInitiated CoverageBuyLow
i
10/23/2019Bank of AmericaInitiated CoverageBuy$35.00 ➝ $29.00High
i
7/5/2019MacquarieInitiated CoverageOutperform ➝ OutperformLow
i
3/27/2019HSBCInitiated CoverageBuyLow
i
3/4/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$26.82Low
i
10/16/2017Canaccord GenuityBoost Price TargetBuy$38.00N/A
i
7/31/2017Canaccord GenuitySet Price TargetBuy$30.00Low
i
6/6/2017Canaccord GenuitySet Price TargetBuy$30.00Low
i
5/18/2017Canaccord GenuitySet Price TargetBuy$30.00Low
i
4/4/2017Stifel NicolausBoost Price TargetBuy$22.00 ➝ $26.00Medium
i
4/1/2017Canaccord GenuitySet Price TargetBuy$30.00Low
i
3/14/2017Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $22.00Low
i
3/11/2017Canaccord GenuitySet Price TargetBuy$20.00High
i
3/3/2017Canaccord GenuitySet Price TargetBuy$20.00N/A
i
2/14/2017Canaccord GenuitySet Price TargetBuy$20.00N/A
i
1/27/2017Canaccord GenuitySet Price TargetBuy$20.00N/A
i
12/6/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
i
11/1/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
8/3/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
8/2/2016Canaccord GenuityReiterated RatingBuyN/A
i
8/1/2016Stifel NicolausSet Price TargetBuy$18.00 ➝ $20.00N/A
i
6/21/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
(Data available from 4/21/2016 forward)
Hutchison China MediTech logo
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It offers research and development services; and manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma and soft tissue sarcoma, neuroendocrine neoplasms, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. Hutchison China MediTech Limited has collaboration agreement with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Read More

Today's Range

Now: $29.21
$29.03
$29.21

50 Day Range

MA: $28.65
$27.01
$30.39

52 Week Range

Now: $29.21
$18.68
$37.00

Volume

150 shs

Average Volume

233,153 shs

Market Capitalization

$4.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Hutchison China MediTech?

The following Wall Street sell-side analysts have issued research reports on Hutchison China MediTech in the last twelve months: Deutsche Bank Aktiengesellschaft, Mizuho, and Zacks Investment Research.
View the latest analyst ratings for HCM.

What is the current price target for Hutchison China MediTech?

1 Wall Street analysts have set twelve-month price targets for Hutchison China MediTech in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 37.9%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting HCM will reach $40.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $40.00 for Hutchison China MediTech in the next year.
View the latest price targets for HCM.

What is the current consensus analyst rating for Hutchison China MediTech?

Hutchison China MediTech currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCM will outperform the market and that investors should add to their positions of Hutchison China MediTech.
View the latest ratings for HCM.

What other companies compete with Hutchison China MediTech?

How do I contact Hutchison China MediTech's investor relations team?

Hutchison China MediTech's physical mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company's listed phone number is 852-2121-8200 and its investor relations email address is [email protected] The official website for Hutchison China MediTech is www.chi-med.com.